Lanlijen Menthol Pain Relief

Description

No relevant information is available for SPL code 34089-3.

Uses and Indications

This drug is indicated for the temporary relief of minor aches and pains associated with sore muscles and joints, including those related to arthritis, backache, strains, and sprains.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

For adults and children aged 12 years and older, the recommended dosage is to apply a thin film of the medication over the affected areas, not exceeding four applications per day. It is not necessary to massage the area after application.

For children under 12 years of age, it is advised to consult a physician for appropriate dosing and administration guidance.

Contraindications

The product is contraindicated in the following situations:

Application is prohibited on wounds or damaged skin due to the risk of exacerbating the condition. It should not be applied to irritated skin or in cases where excessive irritation develops, as this may lead to further skin complications. Concurrent use with other topical formulations, including creams, sprays, ointments, or liniments, is contraindicated to avoid potential interactions or adverse effects. Additionally, the use of heating pads or devices in conjunction with this product is not recommended, as it may increase the risk of skin irritation or burns. Bandaging the area after application is also contraindicated to ensure proper skin ventilation and to prevent adverse reactions.

Warnings and Precautions

For external use only. This product is flammable; therefore, it should be kept away from excessive heat or open flame. Healthcare professionals should advise patients to consult a doctor prior to use if they have sensitive skin.

Patients are instructed to discontinue use and contact their healthcare provider if conditions worsen, symptoms persist for more than 7 days, or if symptoms clear up and then reoccur. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted.

General precautions must be observed to ensure safe use of this product. It is essential to avoid contact with the eyes and mucous membranes. The product should not be applied to wounds, damaged skin, or irritated skin. If excessive irritation develops, use should be discontinued. Additionally, this product should not be used in conjunction with other creams, sprays, ointments, or liniments, nor should it be applied with a heating pad or device. It is recommended to store the product in a cool, dry place and to avoid bandaging the area after application.

No specific laboratory tests are required for the safe use of this product.

Side Effects

Patients should be aware that the product is for external use only and is flammable; it should be kept away from excessive heat or open flame.

In clinical practice, it is advised that patients consult a doctor prior to use if they have sensitive skin. Additionally, if conditions worsen, or if symptoms persist for more than 7 days, or if symptoms clear up and then reoccur, patients should discontinue use and seek medical advice.

For children under 12 years of age, it is recommended to consult a physician before using this product.

Drug Interactions

Co-administration of this product with other topical formulations, such as creams, sprays, ointments, or liniments, is contraindicated. The use of heating pads or devices in conjunction with this product is also not recommended, as it may lead to adverse effects.

There are no specific interactions identified with laboratory tests associated with this product. Therefore, routine laboratory monitoring is not required.

Packaging & NDC

Below are the non-prescription pack sizes of Lanlijen Menthol Pain Relief (menthol). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 12 years of age should consult a physician prior to use. For adolescents and children aged 12 years and older, the recommended dosage is to apply a thin film over the affected areas up to four times daily. Massage of the application site is not necessary.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The safety of this drug during pregnancy has not been established, and potential risks to fetal outcomes are not fully understood. Therefore, it is essential for women of childbearing potential to seek medical advice to weigh the benefits and risks associated with the use of this medication during pregnancy and lactation.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage in the provided sections of the Summary of Product Characteristics (SPL), healthcare professionals are advised to exercise caution and consider general principles of management for suspected overdosage cases.

Recommended Actions In the event of an overdosage, it is essential for healthcare providers to assess the patient's clinical status and initiate appropriate supportive care. Monitoring of vital signs and symptomatic treatment should be prioritized.

Potential Symptoms While specific symptoms related to overdosage are not detailed, healthcare professionals should remain vigilant for any unusual or severe reactions that may arise, given the lack of documented information.

Management Procedures Healthcare professionals are encouraged to consult local poison control centers or toxicology experts for guidance on the management of overdosage. In cases where the substance is known to have a specific antidote or treatment protocol, such measures should be implemented promptly.

In summary, due to the absence of detailed overdosage information, a cautious and supportive approach is recommended, with an emphasis on monitoring and symptomatic management.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question. Further studies may be necessary to elucidate these aspects of nonclinical toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is accidentally ingested. It is important to instruct patients not to apply the product to wounds or damaged skin, as well as to avoid application on irritated skin or if excessive irritation develops.

Patients should be informed that the product should not be used in conjunction with other creams, sprays, ointments, or liniments, and that it should not be used with heating pads or devices. Additionally, healthcare providers should emphasize the importance of avoiding contact with the eyes or mucous membranes.

Patients should be instructed to store the product in a cool, dry place and to refrain from bandaging the area after application. It is advisable for patients with sensitive skin to consult a physician before use. Healthcare providers should also inform patients to discontinue use and seek medical advice if their condition worsens, if symptoms persist for more than 7 days, or if symptoms clear up and then reoccur.

Finally, it is essential to remind patients that children under 12 years of age should consult a physician before using the product.

Storage and Handling

The product is supplied in a package configuration that includes specific NDC numbers. It is essential to store the product in a cool, dry place to maintain its integrity and effectiveness. Proper storage conditions are crucial for ensuring the quality of the product throughout its shelf life.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Lanlijen Menthol Pain Relief, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)